Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Gains from Sales and Divestitures (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 15 years of Gains from Sales and Divestitures data on record, last reported at $86000.0 in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 28.36% year-over-year to $86000.0; the TTM value through Dec 2025 reached $86000.0, up 28.36%, while the annual FY2025 figure was $86000.0, 28.36% up from the prior year.
  • Gains from Sales and Divestitures reached $86000.0 in Q4 2025 per LCTX's latest filing, up from $67000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $86000.0 in Q4 2025 and bottomed at $16000.0 in Q1 2021.
  • Average Gains from Sales and Divestitures over 5 years is $56736.8, with a median of $67000.0 recorded in 2024.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 34.04% in 2022, then soared 400.0% in 2023.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $47000.0 in 2021, then tumbled by 34.04% to $31000.0 in 2022, then skyrocketed by 158.06% to $80000.0 in 2023, then fell by 16.25% to $67000.0 in 2024, then rose by 28.36% to $86000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $86000.0 in Q4 2025, $67000.0 in Q3 2025, and $67000.0 in Q2 2025.